
Richard M Tsai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8514548/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature, 2017, 549, 523-527.	27.8	852
2	Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. Science Translational Medicine, 2020, 12, .	12.4	353
3	Discriminative Accuracy of [¹⁸ F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	7.4	298
4	¹⁸ Fâ€flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. Annals of Neurology, 2017, 82, 622-634.	5.3	148
5	18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimer's Research and Therapy, 2019, 11, 13.	6.2	121
6	Associations between [¹⁸ F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology, 2018, 90, e282-e290.	1.1	113
7	Therapy and clinical trials in frontotemporal dementia: past, present, and future. Journal of Neurochemistry, 2016, 138, 211-221.	3.9	109
8	Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome. JAMA Neurology, 2020, 77, 215.	9.0	81
9	CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology, 2018, 90, e273-e281.	1.1	75
10	Distinct tau PET patterns in atrophyâ€defined subtypes of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 335-344.	0.8	73
11	Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy. Molecular Neurodegeneration, 2020, 15, 2.	10.8	69
12	Treatment of Frontotemporal Dementia. Current Treatment Options in Neurology, 2014, 16, 319.	1.8	64
13	Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy. NeuroImage: Clinical, 2019, 24, 102025.	2.7	53
14	Progression of Microstructural Degeneration in Progressive Supranuclear Palsy and Corticobasal Syndrome: A Longitudinal Diffusion Tensor Imaging Study. PLoS ONE, 2016, 11, e0157218.	2.5	40
15	An 8â€week, openâ€label, doseâ€finding study of nimodipine for the treatment of progranulin insufficiency from <i>GRN</i> gene mutations. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 507-512.	3.7	32
16	Clinical Trials: Past, Current, and Future for Atypical Parkinsonian Syndromes. Seminars in Neurology, 2014, 34, 225-234.	1.4	19
17	Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 28, 29-35.	2.2	18
18	Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI. Journal of Alzheimer's Disease, 2016, 51, 227-236.	2.6	14

#	Article	IF	CITATIONS
19	The Chinese Verbal Learning Test Specifically Assesses Hippocampal State. American Journal of Alzheimer's Disease and Other Dementias, 2015, 30, 412-416.	1.9	3